A Phase 2 interventional study of Efgartigimod and Placebo in Primary Sjögren's Syndrome, sponsored by argenx. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
Primary Sjogren Syndrome (pSS) is an autoimmune disease with still unmet treatment needs. Efgartigimod, a human FcRn antagonist, has the potential to successfully treat pSS and improve disease manifestations by the reduction of IgG autoantibodies and immune complexes in pSS. The study design is randomized, double-blinded, and placebo-controlled to evaluate the effect of efgartigimod administered as an IV infusion compared to placebo. The study consists of a treatment period when all participants will receive infusions of IP/placebo for 24 weeks. At the end of the randomized treatment period, eligible participants may roll over to an OLE study or remain in this study through the end of the 56-day follow-up period.
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients receiving infusions of Efgartigimod IV
Biological: Efgartigimod
patients receiving infusions of placebo IV
Biological: Placebo
Patients receiving efgartigimod infusions
Patients receiving placebo infusions
Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24
A Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responder is defined as improvements in at least 3 of the 5 items of CRESS (systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function and serology. The score ranges from 0 to 9 (higher score = worse symptoms).
Time frame: Week 24
Number of Participants With TEAEs, AESI, and SAEs
A treatment-emergent adverse event (TEAE): adverse events reported from the first dose up to and including 60 days after the final dose were considered treatment-emergent. Serious adverse event (SAE): adverse event that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other situations. Adverse event of special interest (AESI): adverse event related to 'Infections and infestations'.
Time frame: Up to 32 weeks
Percentage of Participants With MCII in ESSDAI at Week 24
European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Minimally clinically important improvement (MCII) in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Week 24.
Time frame: Week 24
Percentage of Participants With Low Disease Activity in ESSDAI at Week 24
ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Week 24.
Time frame: Week 24
Percentage of Participants With MCII in clinESSDAI at Week 24
Clinical (clin)ESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Minimal clinically important improvement (MCII) in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Week 24.
Time frame: Week 24
Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Week 24.
Time frame: Week 24
Percentage of Participants With MCII in ESSPRI at Week 24
Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least ≥15% at Week 24. ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).
Time frame: Week 24
Change From Baseline in ESSDAI Score at Week 24
ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score = worse symptoms).
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in clinESSDAI Score at Week 24
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms).
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in ESSPRI Score at Week 24
ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants With STAR Score of at Least 5 at Week 24
Sjögren's Tool for Assessing Response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a score of at least 5 points. Due to the weighting, participants must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome).
Time frame: Week 24
Plasma Concentration of Efgartigimod
Serum samples were collected at indicated time points to assess the pharmacokinetic (PK) profile of efgartigimod.
Time frame: Pre-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, and 20; 30 minutes post-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage Change From Baseline in Total IgG Levels in Serum at Week 24
Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum.
Time frame: Baseline (Day 1) and Week 24
Number of Participants With ADA Against Efgartigimod in Serum
Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Treatment-unaffected ADA was defined as participants who had a baseline positive sample, but the titer value did not increase 4-fold or more compared to baseline.
Time frame: Up to Week 24
This Phase 2, double-blinded study was conducted in adult participants with primary Sjögren's disease (pSjD) at 15 investigational sites in 3 countries (Belgium, Hungary, and Poland) between 08-May-2023 and 12-Feb-2024.
| Milestone | Efgartigimod | Placebo |
|---|---|---|
| Started | 23 | 11 |
| Completed | 20 | 7 |
| Not completed | 3 | 4 |
| Withdrew: Prohibited medication used | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
A Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responder is defined as improvements in at least 3 of the 5 items of CRESS (systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function and serology. The score ranges from 0 to 9 (higher score = worse symptoms).
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 | 45.5 (26.92 to 65.34) | 11.1 (1.99 to 43.50) |
A treatment-emergent adverse event (TEAE): adverse events reported from the first dose up to and including 60 days after the final dose were considered treatment-emergent. Serious adverse event (SAE): adverse event that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other situations. Adverse event of special interest (AESI): adverse event related to 'Infections and infestations'.
| Participants | Efgartigimod | Placebo |
|---|---|---|
| Any TEAE | 20 | 7 |
| Any AESI | 15 | 5 |
| Any SAE | 1 | 0 |
European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Minimally clinically important improvement (MCII) in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Week 24.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With MCII in ESSDAI at Week 24 | 72.7 (51.85 to 86.85) | 55.6 (26.67 to 81.12) |
ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Week 24.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With Low Disease Activity in ESSDAI at Week 24 | 59.1 (38.73 to 76.74) | 22.2 (6.32 to 54.74) |
Clinical (clin)ESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Minimal clinically important improvement (MCII) in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Week 24.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With MCII in clinESSDAI at Week 24 | 77.3 (56.56 to 89.88) | 77.8 (45.26 to 93.68) |
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Week 24.
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24 | 59.1 (38.73 to 76.74) | 33.3 (12.06 to 64.58) |
Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least ≥15% at Week 24. ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With MCII in ESSPRI at Week 24 | 31.8 (16.36 to 52.68) | 33.3 (12.06 to 64.58) |
ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score = worse symptoms).
| score on a scale | Efgartigimod | Placebo |
|---|---|---|
| Change From Baseline in ESSDAI Score at Week 24 | -5.0 (-10.0 to -4.0) | -4.0 (-13.0 to -1.0) |
clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms).
| score on a scale | Efgartigimod | Placebo |
|---|---|---|
| Change From Baseline in clinESSDAI Score at Week 24 | -7.0 (-12.0 to -3.0) | -4.0 (-17.0 to -3.0) |
ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).
| score on a scale | Efgartigimod | Placebo |
|---|---|---|
| Change From Baseline in ESSPRI Score at Week 24 | -0.500 (-1.333 to 0.333) | -0.833 (-1.333 to -0.333) |
Sjögren's Tool for Assessing Response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a score of at least 5 points. Due to the weighting, participants must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome).
| Percentage of participants | Efgartigimod | Placebo |
|---|---|---|
| Percentage of Participants With STAR Score of at Least 5 at Week 24 | 54.5 (34.66 to 73.08) | 33.3 (12.06 to 64.58) |
Serum samples were collected at indicated time points to assess the pharmacokinetic (PK) profile of efgartigimod.
| Nanograms per milliliter (ng/mL) | Efgartigimod |
|---|---|
| Day 1: Pre-dose | NA ± NA |
| Day 1: 30 minutes post-dose | 179391 ± 79751 |
| Week 1: Pre-dose | 17238 ± 37356 |
| Week 1: 30 minutes post-dose | 187300 ± 73091 |
| Week 2: Pre-dose | 22470 ± 42838 |
| Week 2: 30 minutes post-dose | 205148 ± 52448 |
| Week 4: Pre-dose | 38595 ± 65900 |
| Week 4: 30 minutes post-dose | 206414 ± 102089 |
| Week 8: Pre-dose | 14193 ± 5753 |
| Week 8: 30 minutes post-dose | 203505 ± 89762 |
| Week 12: Pre-dose | 13096 ± 4523 |
| Week 12: 30 minutes post-dose | 200856 ± 138766 |
| Week 16: Pre-dose | 12676 ± 5835 |
| Week 16: 30 minutes post-dose | 261647 ± 215940 |
| Week 20: Pre-dose | 12942 ± 4472 |
| Week 20: 30 minutes post-dose | 194944 ± 81722 |
| Week 24: 30 minutes post-dose | 14284 ± 4987 |
Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum.
| Percentage change | Efgartigimod | Placebo |
|---|---|---|
| Percentage Change From Baseline in Total IgG Levels in Serum at Week 24 | -57.172 ± 17.7376 | 0.279 ± 9.5193 |
Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Treatment-unaffected ADA was defined as participants who had a baseline positive sample, but the titer value did not increase 4-fold or more compared to baseline.
| Participants | Efgartigimod | Placebo |
|---|---|---|
| Treatment-boosted ADA | 1 | 0 |
| Treatment-induced ADA | 2 | 0 |
| Treatment-unaffected ADA | 11 | 3 |
Collected over Up to 32 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod | 0/23 (0%) | 1/23 (4.3%) | 20/23 (87%) |
| Placebo | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Event | Efgartigimod | Placebo |
|---|---|---|
| VasospasmVascular disorders | 1/23 | 0/11 |
| Event | Efgartigimod | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/23 | 2/11 |
| NasopharyngitisInfections and infestations | 4/23 | 1/11 |
| HeadacheNervous system disorders | 4/23 | 1/11 |
| InfluenzaInfections and infestations | 3/23 | 0/11 |
| Urinary tract infectionInfections and infestations | 3/23 | 1/11 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/23 | 1/11 |
| PalpitationsCardiac disorders | 0/23 | 1/11 |
| Motion sicknessEar and labyrinth disorders | 0/23 | 1/11 |
| Abdominal painGastrointestinal disorders | 0/23 | 1/11 |
| Abdominal pain lowerGastrointestinal disorders | 0/23 | 1/11 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment and who were classified according to the planned treatment.
| Age, Continuous(Years) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Mean | 50.1 ± 12.57 | 54.7 ± 12.42 | 51.6 ± 12.52 |
| Sex: Female, Male(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Female | 22 | 11 | 33 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 22 | 11 | 33 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod | Placebo | Total |
|---|---|---|---|
| White | 22 | 11 | 33 |
| Unknown | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2023 to primary completion in Jan 2024, 9 months.
Results were first posted in Jul 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa